News

Hypercon Technology Deal Signed between Halozyme and Vertex

Yuvraj — Thu, 09 Apr 2026 10:56:27 +0000

Halozyme Therapeutics has entered into a global exclusive partnership and licence agreement with Vertex Pharmaceuticals through its subsidiary Halozyme Hypercon, marking a new step in advancing drug delivery capabilities. The deal gives Vertex access to the Hypercon platform, which it can apply across up to three specified drug targets, underlining a targeted approach to next-generation […]

The post Hypercon Technology Deal Signed between Halozyme and Vertex first appeared on World Pharma Today.

Gilead Advances ADC Pipeline Expansion with $3B Tubulis Deal

Yuvraj — Wed, 08 Apr 2026 13:35:51 +0000

Gilead Sciences has agreed to acquire Germany-based Tubulis in a deal valued at $3.15 billion upfront, with an additional $1.85 billion tied to milestones, as the company advances its position in the rapidly evolving antibody-drug conjugate segment. The acquisition brings in a late-stage asset nearing pivotal trials and marks a significant step in strengthening the […]

The post Gilead Advances ADC Pipeline Expansion with $3B Tubulis Deal first appeared on World Pharma Today.

Neurocrine Nears $2.5bn Soleno Therapeutics Acquisition

Yuvraj — Tue, 07 Apr 2026 06:53:33 +0000

Neurocrine Biosciences is close to securing a more than $2.5bn acquisition of Soleno Therapeutics, the developer of a treatment for a rare genetic form of obesity. The talks, described as advanced, highlight how midsized drugmakers are increasingly pursuing strategic deals to expand their portfolios. Neurocrine, known for its focus on neuropsychiatric medicines, is seeking to […]

The post Neurocrine Nears $2.5bn Soleno Therapeutics Acquisition first appeared on World Pharma Today.

Biogen to Acquire Apellis for $5.6 Billion in Major Deal

Yuvraj — Tue, 07 Apr 2026 06:21:05 +0000

Biogen Inc. has agreed to acquire Apellis Pharmaceuticals Inc. for $5.6 billion, in a move that significantly expands its presence in immunology and rare diseases. The Biogen to Acquire Apellis deal stands among the company’s largest transactions to date, reinforcing its efforts to diversify beyond its core therapeutic areas. As part of the agreement, the […]

The post Biogen to Acquire Apellis for $5.6 Billion in Major Deal first appeared on World Pharma Today.

Trump Announces 100% US Pharma Tariffs for Patented Drugs

Yuvraj — Sat, 04 Apr 2026 08:55:16 +0000

The US pharma tariffs policy has been formalised through an executive order signed by Donald Trump, introducing tariffs of up to 100% on imported branded medicines. The measure targets pharmaceutical companies that have not entered into drug pricing agreements with the US government or committed to establishing manufacturing operations domestically. Positioned as a national security […]

The post Trump Announces 100% US Pharma Tariffs for Patented Drugs first appeared on World Pharma Today.

Biomaterials and Local Drug Delivery in Implant Surgery

Yuvraj — Sat, 04 Apr 2026 08:11:17 +0000

Advances in biomaterials and localized drug delivery systems are transforming implant surgery across both medical and dental disciplines. Traditionally, implant success relied primarily on mechanical stability and surgical technique. Today, innovations in bioactive materials, surface engineering, and controlled drug delivery are improving osseointegration, reducing inflammation, and supporting faster healing. These developments reflect broader trends in […]

The post Biomaterials and Local Drug Delivery in Implant Surgery first appeared on World Pharma Today.

UK-US Pharma Trade Deal Drives Tariff Cuts, Pricing Shift

Yuvraj — Sat, 04 Apr 2026 08:03:56 +0000

Britain has finalised a UK-US pharma trade deal, securing tariff-free access for UK-made medicines to the United States while committing to higher domestic spending and pricing adjustments for new drugs. The agreement, part of a broader bilateral trade framework first outlined in December and signed in June 2025, establishes zero tariffs on pharmaceutical exports to […]

The post UK-US Pharma Trade Deal Drives Tariff Cuts, Pricing Shift first appeared on World Pharma Today.

Eli Lilly to Acquire Centessa Pharmaceuticals in $7.8B Deal

Yuvraj — Fri, 03 Apr 2026 08:47:22 +0000

Eli Lilly & Co. is set to acquire Centessa Pharmaceuticals Plc in a transaction worth up to $7.8 billion, underscoring its push to broaden its drug development pipeline. The Centessa Pharmaceuticals deal highlights the company’s effort to expand into therapeutic areas beyond its current core focus, particularly within neuroscience. Under the terms announced Tuesday, Lilly will […]

The post Eli Lilly to Acquire Centessa Pharmaceuticals in $7.8B Deal first appeared on World Pharma Today.

D2 Solutions Highlights Medication Access Delays in U.S.

Yuvraj — Fri, 03 Apr 2026 08:34:33 +0000

New findings from healthcare consulting and technology company D2 Solutions indicate that medication access delays are influencing whether patients initiate prescribed therapies, with confusion and administrative hurdles emerging as key barriers. Based on a survey of 1,000 U.S. adults aged 25 and older, 21% reported postponing the start of a medication, underscoring how access-related issues […]

The post D2 Solutions Highlights Medication Access Delays in U.S. first appeared on World Pharma Today.

Johnson & Johnson Wins DARZALEX Self-Administration EU Nod

Yuvraj — Wed, 01 Apr 2026 06:25:12 +0000

Johnson & Johnson has received a key regulatory endorsement in Europe, marking a significant shift in how oncology treatments can be administered. The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has approved a Type II variation to the label of DARZALEX (daratumumab) subcutaneous (SC) formulation. This update allows patients […]

The post Johnson & Johnson Wins DARZALEX Self-Administration EU Nod first appeared on World Pharma Today.